@article{abd5bcc64dbe4fdf85f33cfffc6222c9,
title = "CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease",
abstract = "Introduction: CT-P13 was developed as an infliximab biosimilar in 2013. The primary structure of CT-P13 is identical to that of original infliximab and it has highly similar higher order structure, physiochemical characteristics, and biological properties. To date, data from real-life cohorts and randomized controlled trials show comparable clinical efficacy, safety and immunogenicity of biosimilar CT-P13, and the original reference medicinal Product (RMP). Areas covered: This article reviews the comparability of CT-P13 and the RMP and focuses on the emerging clinical trial and observational cohorts data on efficacy and safety of CT-P13 in inflammatory bowel disease (IBD) patients. The development of a subcutaneous formulation of Infliximab CT-P13 is also addressed. Expert opinion: There is a plethora of evidence to show CT-P13 is non-inferior to infliximab RMP in IBD and that a switch from RMP to this biosimilar is feasible and safe. However, interchangeability and multiple switches can still not be endorsed for introduction into clinical practice.",
keywords = "Anti TNF, CT-P13, Crohn{\textquoteright}s disease, biosimilar, drug monitoring, original infliximab, ulcerative colitis",
author = "Ahmad Albshesh and Shomron Ben-Horin",
note = "Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Informa UK Limited, trading as Taylor & Francis Group.",
year = "2019",
month = oct,
day = "3",
doi = "10.1080/14712598.2019.1653848",
language = "אנגלית",
volume = "19",
pages = "971--978",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "10",
}
